GKT 831

Drug Profile

GKT 831

Alternative Names: GKT-137831; GKT-831; UNII-45II35329V

Latest Information Update: 21 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenKyoTex
  • Developer GenKyoTex; University of California, Davis; University of California, San Diego
  • Class Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action NOX1 protein inhibitors; NOX4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Primary biliary cirrhosis
  • No development reported Hepatic fibrosis; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Systemic scleroderma
  • Discontinued Atherosclerosis; Bone disorders; Eye disorders

Most Recent Events

  • 28 Jun 2017 Genkyotex plans a phase II trial for Type 1 diabetes mellitus (associated with diabetic kidney disease) in Australia
  • 27 Jun 2017 Phase-II clinical trials in Primary biliary cirrhosis in USA (PO)
  • 05 May 2017 Discontinued - Preclinical for Atherosclerosis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top